A detailed history of Susquehanna International Group, LLP transactions in 89bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 340,071 shares of ETNB stock, worth $2.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
340,071
Previous 309,416 9.91%
Holding current value
$2.67 Million
Previous $2.48 Million 1.53%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $225,620 - $296,127
30,655 Added 9.91%
340,071 $2.52 Million
Q2 2024

Aug 15, 2024

BUY
$7.31 - $10.9 $946,308 - $1.41 Million
129,454 Added 71.93%
309,416 $2.48 Million
Q1 2024

May 07, 2024

BUY
$8.13 - $13.77 $111,803 - $189,365
13,752 Added 8.27%
179,962 $2.09 Million
Q4 2023

Feb 14, 2024

SELL
$6.66 - $16.03 $1.43 Million - $3.44 Million
-214,857 Reduced 56.38%
166,210 $1.86 Million
Q3 2023

Nov 14, 2023

BUY
$15.06 - $19.41 $2.01 Million - $2.59 Million
133,271 Added 53.78%
381,067 $5.88 Million
Q2 2023

Aug 11, 2023

SELL
$14.15 - $22.03 $5.61 Million - $8.73 Million
-396,305 Reduced 61.53%
247,796 $4.7 Million
Q1 2023

May 16, 2023

BUY
$10.48 - $16.94 $4.33 Million - $6.99 Million
412,851 Added 178.53%
644,101 $9.81 Million
Q4 2022

Feb 14, 2023

BUY
$5.52 - $12.73 $1.28 Million - $2.94 Million
231,250 New
231,250 $2.94 Million
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $77,649 - $149,355
37,153 Added 202.29%
55,519 $179,000
Q1 2022

May 16, 2022

BUY
$3.45 - $14.99 $11,723 - $50,936
3,398 Added 22.7%
18,366 $69,000
Q1 2021

May 17, 2021

BUY
$20.22 - $26.73 $302,652 - $400,094
14,968 New
14,968 $354,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $365M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.